The round, backed by AmorePacific's corporate venturing unit, will support the clinical advancement of Elastagen's cosmetic surgery technology.
Australia-based dermatology technology developer Elastagen has closed a A$13m ($9.1m) series B round that included funding from AmorePacific Ventures, the corporate venturing fund owned by Korea-based beauty company AmorePacific.
The round also included Korea Investment Partners, Wellcome Trust, Brandon Capital Partners, GBS Ventures and ATP Innovations.
Elastagen is developing a tropoelastin platform that can be used for cosmetic surgery on atrophic scars like stretch marks and acne scars, as well as dermaesthetics and tissue repair. The funding will help advance…
